ABU DHABI, nineteenth May, 2021 (WAM) — The Emirati Genome Programme expanded its attain with new pattern assortment centres which were added via devoted facilities across Burjeel Hospital’s network in Abu Dhabi.
The announcement, which was made throughout an attended by senior officers and healthcare professionals from Burjeel Hospital in addition to G42 Healthcare, marks the start of necessary scientific collaborations between the 2 organisations.
As a part of the brand new partnership, residents in the Emirate can now take part in this system by visiting Burjeel Medical City – MBZ City, Burjeel Oasis Medical Centre – Madinat Zayed, Burjeel Medical Centre – Deerfields Mall, Burjeel Medical Centre at Al Shamkha or Burjeel Royal Hospital, Al Ain.
During the occasion, outstanding healthcare professionals together with Dr. Humaid Al Shamsi, Director of Burjeel Cancer Institute ( BCI ) & VPS Oncology at VPS Healthcare and Head of the Emirates Oncology Society, Dr. Rihan Saafan, Head of Obstetrics and Gynecology and Dr. Zainul Aabideen, Head of Paediatric, and Paediatric Haematology and Oncology at Burjeel Medical City make clear the worth and impression of genomics on the transformation of healthcare by tailoring sufferers’ administration plans to ship extra personalised medical care.
John Sunil, Regional CEO Burjeel Group Abu Dhabi & Al Ain Region, VPS Healthcare, stated, “We are excited to change into a part of such key nationwide programmes which might be set to remodel healthcare in Abu Dhabi and ship on its imaginative and prescient of creating the emirate as a hub for medical analysis and innovation. We encourage all Emiratis to take part in the Emirati Genome Programme, which is concentrated on delivering higher insights into genetic variations of the native inhabitants that may in the end help constructive affected person outcomes on the long term. All our centres are geared up with greatest-in-class medical and help companies delivered by effectively-skilled, accredited, and expert professionals to facilitate ease of participation in the programme.”
The Emirati Genome Programme goals to present preventive and personalised healthcare for the Emirati inhabitants. This is achieved by understanding residents’ genetic make-up to ship the following wave of key improvements that holds the promise for a more healthy area people now and for future generations.
On his half, Ashish Koshy, CEO of G42 Healthcare stated, “The Emirati Genome Programme is designed to allow exact and customised medical remedy that may help a extra strong healthcare system in the UAE. We are happy to see partnerships extending past public entities to personal healthcare companies. With this strategic collaboration, we’re wanting ahead to elevating consciousness amongst the residents to higher perceive the constructive impression and relevance of genetics to their lives. Through Burjeel’s in depth network, we might be in a position to present simpler entry for extra volunteers to take part in this system.”